Single studies using the CohortMethod package

Martijn J. Schuemie, Marc A. Suchard and Patrick Ryan 2019-01-19

Contents

1 Introduction							
2	Installation instructions						
3	Data extraction 3.1 Configuring the connection to the server 3.2 Preparing the exposures and outcome(s) 3.3 Extracting the data from the server						
4	Defining the study population	6					
5	Propensity scores 5.1 Fitting a propensity model	7 7					
		7					
		8					
	5.4 Evaluating covariate balance	12					
	5.5 Inspecting select population characteristics	14 15					
6	Follow-up and power	15					
7	Outcome models	16					
	7.1 Fitting a simple outcome model	16					
	7.2 Adding interaction terms	17					
	7.3 Adding covariates to the outcome model	18					
	7.4 Injecting the outcome model	19					
	7.5 Kaplan-Meier plot	20					
	7.6 Time-to-event plot	20					
8	Acknowledgments	21					

1 Introduction

This vignette describes how you can use the CohortMethod package to perform a single new-user cohort study. We will walk through all the steps needed to perform an exemplar study, and we have selected the well-studied topic of the effect of coxibs versus non-selective non-steroidal anti-inflammatory drugs (NSAIDs) on gastrointestinal (GI) bleeding-related hospitalization. For simplicity, we focus on one coxib – celecoxib – and one non-selective NSAID – diclofenac.

2 Installation instructions

Before installing the CohortMethod package make sure you have Java available. Java can be downloaded from www.java.com. For Windows users, RTools is also necessary. RTools can be downloaded from CRAN.

The CohortMethod package is currently maintained in a Github repository, and has dependencies on other packages in Github. All of these packages can be downloaded and installed from within R using the drat package:

```
install.packages("drat")
drat::addRepo("OHDSI")
install.packages("CohortMethod")
```

Once installed, you can type library (Cohort Method) to load the package.

3 Data extraction

The first step in running the CohortMethod is extracting all necessary data from the database server holding the data in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) format.

3.1 Configuring the connection to the server

We need to tell R how to connect to the server where the data are. CohortMethod uses the DatabaseConnector package, which provides the createConnectionDetails function. Type ?createConnectionDetails for the specific settings required for the various database management systems (DBMS). For example, one might connect to a PostgreSQL database using this code:

The last two lines define the cdmDatabaseSchema and resultSchema variables. We'll use these later to tell R where the data in CDM format live, and where we want to write intermediate tables. Note that for Microsoft SQL Server, databaseschemas need to specify both the database and the schema, so for example cdmDatabaseSchema <- "my_cdm_data.dbo".

3.2 Preparing the exposures and outcome(s)

We need to define the exposures and outcomes for our study. One could use an external cohort definition tools, but in this example we do this by writing SQL statements against the OMOP CDM that populate a table of events in which we are interested. The resulting table should have the same structure as the cohort table in the CDM. This means it should have the fields cohort_definition_id, cohort_start_date, cohort_end_date, and subject_id.

For our example study, we have created a file called coxib VsNonselVsGiBleed.sql with the following contents:

```
cohort_definition_id INT,
  cohort_start_date DATE,
    cohort end date DATE,
    subject_id BIGINT
   );
INSERT INTO @resultsDatabaseSchema.coxibVsNonselVsGiBleed (
    cohort_definition_id,
    cohort_start_date,
    cohort_end_date,
    subject_id
   )
SELECT 1, -- Exposure
   drug_era_start_date,
   drug_era_end_date,
   person_id
FROM @cdmDatabaseSchema.drug_era
WHERE drug_concept_id = 1118084; -- celecoxib
INSERT INTO @resultsDatabaseSchema.coxibVsNonselVsGiBleed (
    cohort definition id,
    cohort_start_date,
    cohort_end_date,
   subject_id
SELECT 2, -- Comparator
   drug_era_start_date,
   drug_era_end_date,
   person_id
FROM @cdmDatabaseSchema.drug_era
WHERE drug_concept_id = 1124300; --diclofenac
INSERT INTO @resultsDatabaseSchema.coxibVsNonselVsGiBleed (
    cohort_definition_id,
    cohort_start_date,
    cohort_end_date,
    subject_id
   )
SELECT 3, -- Outcome
    condition_start_date,
    condition_end_date,
    condition_occurrence.person_id
FROM @cdmDatabaseSchema.condition_occurrence
INNER JOIN @cdmDatabaseSchema.visit_occurrence
    ON condition_occurrence.visit_occurrence_id = visit_occurrence.visit_occurrence_id
WHERE condition_concept_id IN (
        SELECT descendant_concept_id
        FROM @cdmDatabaseSchema.concept_ancestor
        WHERE ancestor_concept_id = 192671 -- GI - Gastrointestinal haemorrhage
    AND visit_occurrence.visit_concept_id IN (9201, 9203);
```

This is parameterized SQL which can be used by the SqlRender package. We use parameterized SQL so we do not have to pre-specify the names of the CDM and result schemas. That way, if we want to run the SQL

on a different schema, we only need to change the parameter values; we do not have to change the SQL code. By also making use of translation functionality in SqlRender, we can make sure the SQL code can be run in many different environments.

In this code, we first read the SQL from the file into memory. In the next line, we replace the two parameter names with the actual values. We then translate the SQL into the dialect appropriate for the DBMS we already specified in the connectionDetails. Next, we connect to the server, and submit the rendered and translated SQL.

If all went well, we now have a table with the events of interest. We can see how many events per type:

3.3 Extracting the data from the server

Now we can tell CohortMethod to define the cohorts based on our events, construct covariates, and extract all necessary data for our analysis.

Important: The target and comparator drug must not be included in the covariates, including any descendant concepts. If the targetId and comparatorId arguments represent real concept IDs, you can set the excludeDrugsFromCovariates argument of the getDbCohortMethodData function to TRUE and automatically the drugs and their descendants will be excluded from the covariates. However, if the targetId and comparatorId arguments do not represent concept IDs, such as in the example above, you will need to manually add the drugs and descendants to the excludedCovariateConceptIds of the covariate settings. In this example code we exclude all NSAIDs from the covariates by pointing to the concept ID of the NSAID class and specifying addDescendantsToExclude = TRUE.

```
cdmDatabaseSchema = cdmDatabaseSchema,
                                           oracleTempSchema = resultsDatabaseSchema,
                                           targetId = 1,
                                           comparatorId = 2,
                                           outcomeIds = 3,
                                           studyStartDate = "",
                                           studyEndDate = "",
                                           exposureDatabaseSchema = resultsDatabaseSchema,
                                           exposureTable = "coxibVsNonselVsGiBleed",
                                           outcomeDatabaseSchema = resultsDatabaseSchema,
                                           outcomeTable = "coxibVsNonselVsGiBleed",
                                           cdmVersion = cdmVersion,
                                           excludeDrugsFromCovariates = FALSE,
                                           firstExposureOnly = TRUE,
                                           removeDuplicateSubjects = TRUE,
                                           restrictToCommonPeriod = FALSE,
                                           washoutPeriod = 180,
                                           covariateSettings = covSettings)
cohortMethodData
```

#> CohortMethodData object
#>

#> Treatment concept ID: 1
#> Comparator concept ID: 2
#> Outcome concept ID(s): 3

There are many parameters, but they are all documented in the CohortMethod manual. The createDefaultCovariateSettings function is described in the FeatureExtraction package. In short, we are pointing the function to the table created earlier and indicating which concept IDs in that table identify the target, comparator and outcome. We instruct that the default set of covariates should be constructed, including covariates for all conditions, drug exposures, and procedures that were found on or before the index date. To customize the set of covariates, please refer to the FeatureExtraction package vignette by typing vignette("UsingFeatureExtraction", package="FeatureExtraction").

All data about the cohorts, outcomes, and covariates are extracted from the server and stored in the cohortMethodData object. This object uses the package ff to store information in a way that ensures R does not run out of memory, even when the data are large.

We can use the generic summary() function to view some more information of the data we extracted:

summary(cohortMethodData)

```
#> CohortMethodData object summary
#>
#> Treatment concept ID: 1
#> Comparator concept ID: 2
#> Outcome concept ID(s): 3
#>
#> Treated persons: 49102
#> Comparator persons: 348558
#>
#> Outcome counts:
    Event count Person count
#> 3
           27636
                        18141
#>
#> Covariates:
```

```
#> Number of covariates: 54112
#> Number of non-zero covariate values: 161150531
```

3.3.1 Saving the data to file

Creating the cohortMethodData file can take considerable computing time, and it is probably a good idea to save it for future sessions. Because cohortMethodData uses ff, we cannot use R's regular save function. Instead, we'll have to use the saveCohortMethodData() function:

```
saveCohortMethodData(cohortMethodData, "coxibVsNonselVsGiBleed")
```

We can use the loadCohortMethodData() function to load the data in a future session.

3.3.2 Defining new users

Typically, a new user is defined as first time use of a drug (either target or comparator), and typically a washout period (a minimum number of days prior first use) is used to make sure it is truly first use. When using the CohortMethod package, you can enforce the necessary requirements for new use in three ways:

- 1. When creating the cohorts in the database, for example when using a cohort definition tool.
- 2. When loading the cohorts using the getDbCohortMethodData function, you can use the firstExposureOnly, removeDuplicateSubjects, restrictToCommonPeriod, and washoutPeriod arguments. (As shown in the example above).
- 3. When defining the study population using the createStudyPopulation function (see below) using the firstExposureOnly, removeDuplicateSubjects, restrictToCommonPeriod, and washoutPeriod arguments.

The advantage of option 1 is that the input cohorts are already fully defined outside of the CohortMethod package, and for example external cohort characterization tools can be used on the same cohorts used in this package. The advantage of options 2 and 3 is that it saves you the trouble of limiting to first use yourself, for example allowing you to directly use the drug_era table in the CDM. Option 2 is more efficient than 3, since only data for first use will be fetched, while option 3 is less efficient but allows you to compare the original cohorts to the study population.

4 Defining the study population

Typically, the exposure cohorts and outcome cohorts will be defined independently of each other. When we want to produce an effect size estimate, we need to further restrict these cohorts and put them together, for example by removing exposed subjects that had the outcome prior to exposure, and only keeping outcomes that fall within a defined risk window. For this we can use the createStudyPopulation function:

Note that we've set firstExposureOnly and removeDuplicateSubjects to FALSE, and washoutPeriod to zero because we already filtered on these arguments when using the getDbCohortMethodData function. During loading we set restrictToCommonPeriod to FALSE, and we do the same here because we do not want to force the comparison to restrict only to time when both drugs are recorded. We specify the outcome ID we will use, and that people with outcomes prior to the risk window start date will be removed. The risk window is defined as starting at the index date (riskWindowStart = 0 and addExposureDaysToStart = FALSE), and the risk windows ends 30 days after exposure ends (riskWindowEnd = 30 and addExposureDaysToEnd = TRUE). Note that the risk windows are truncated at the end of observation or the study end date. We also remove subjects who have no time at risk. To see how many people are left in the study population we can always use the getAttritionTable function:

```
getAttritionTable(studyPop)
```

One additional filtering step that is often used is matching or trimming on propensity scores, as will be discussed next.

5 Propensity scores

The CohortMethod can use propensity scores to adjust for potential confounders. Instead of the traditional approach of using a handful of predefined covariates, CohortMethod typically uses thousands to millions of covariates that are automatically constructed based on conditions, procedures and drugs in the records of the subjects.

5.1 Fitting a propensity model

We can fit a propensity model using the covariates constructed by the getDbcohortMethodData() function:

```
ps <- createPs(cohortMethodData = cohortMethodData, population = studyPop)</pre>
```

The createPs() function uses the Cyclops package to fit a large-scale regularized logistic regression.

To fit the propensity model, Cyclops needs to know the hyperparameter value which specifies the variance of the prior. By default Cyclops will use cross-validation to estimate the optimal hyperparameter. However, be aware that this can take a really long time. You can use the prior and control parameters of the createPs() to specify Cyclops behavior, including using multiple CPUs to speed-up the cross-validation.

5.2 Propensity score diagnostics


We can compute the area under the receiver-operator curve (AUC) for the propensity score model:

```
computePsAuc(ps)
```

```
#> [1] 0.8157477
```

We can also plot the propensity score distribution, although we prefer the preference score distribution:

```
plotPs(ps, scale = "preference", showCountsLabel = TRUE, showAucLabel = TRUE, showEquiposeLabel = TRUE)
```



It is also possible to inspect the propensity model itself by showing the covariates that have non-zero coefficients:

```
propensityModel <- getPsModel(ps, cohortMethodData)
head(propensityModel)</pre>
```


#>		${\tt coefficient}$	${\tt covariateId}$	covariateName
#>	(Intercept)	-1.7741683	NA	(Intercept)
#>	27	1.4330013	2007006	index year: 2007
#>	855	1.3144444	2101660504	s on knee joint; total knee arthroplasty
#>	1868	1.2024638	4253901210	to index: Juvenile rheumatoid arthritis
#>	5	-1.1604170	3003	age group: 15-19
#>	28	0.9963337	2008006	index year: 2008

One advantage of using the regularization when fitting the propensity model is that most coefficients will shrink to zero and fall out of the model. It is a good idea to inspect the remaining variables for anything that should not be there, for example variations of the drugs of interest that we forgot to exclude.

5.3 Using the propensity score


We can use the propensity scores to trim, stratify, match, or weigh our population. For example, one could trim to equipoise, meaning only subjects with a preference score between 0.25 and 0.75 are kept:

```
trimmedPop <- trimByPsToEquipoise(ps)
plotPs(trimmedPop, ps, scale = "preference")</pre>
```




Instead (or additionally), we could stratify the population based on the propensity score:

```
stratifiedPop <- stratifyByPs(ps, numberOfStrata = 5)
plotPs(stratifiedPop, ps, scale = "preference")</pre>
```



We can also match subjects based on propensity scores. In this example, we're using one-to-one matching: matchedPop <- matchOnPs(ps, caliper = 0.2, caliperScale = "standardized logit", maxRatio = 1) plotPs(matchedPop, ps)



Note that for both stratification and matching it is possible to specify additional matching criteria such as age and sex using the stratifyByPsAndCovariates() and matchOnPsAndCovariates() functions, respectively.


We can see the effect of trimming and/or matching on the population using the getAttritionTable function:

getAttritionTable(matchedPop)

#>	description	targetPersons	comparatorPe
#>	1 Original cohorts	104225	5:
#>	2 First exp. only & removed subs in both cohorts & 180 days of obs. prior	49102	34
#>	No prior outcome	47411	3:
#>	4 Have at least 1 days at risk	47377	33
#>	5 Matched on propensity score	44960	4

Or, if we like, we can plot an attrition diagram:

drawAttritionDiagram(matchedPop)




5.4 Evaluating covariate balance

To evaluate whether our use of the propensity score is indeed making the two cohorts more comparable, we can compute the covariate balance before and after trimming, matching, and/or stratifying:

```
balance <- computeCovariateBalance(matchedPop, cohortMethodData)
plotCovariateBalanceScatterPlot(balance, showCovariateCountLabel = TRUE, showMaxLabel = TRUE)</pre>
```

#> Warning: Removed 10591 rows containing missing values (geom_point).





The 'before matching' population is the population as extracted by the getDbCohortMethodData function,

5.5 Inspecting select population characteristics

It is customary to include a table in your paper that lists some select population characteristics before and after matching/stratification/trimming. This is usually the first table, and so will be referred to as 'table 1'. To generate this table, you can use the createCmTable1 function:

createCmTable1(balance)

	Before matching			After matching		
	Target	Comparator		Target	Comparator	
Characteristic	%	%	Std. diff	%	%	Std. diff
Age group 00-04	0.1	0.1	0.02	0.1	0.0	0.02
05-09	0.3	0.2	0.02	0.2	0.2	0.00
10-14	0.8	2.3	-0.12	0.8	0.7	0.02
15-19	2.7	11.1	-0.34	2.8	2.3	0.04
20-24	2.2	6.5	-0.21	2.3	2.0	0.02
25-29	3.9	9.6	-0.23	4.1	3.7	0.02
30-34	5.7	11.0	-0.19	6.0	5.7	0.01
35-39	7.0	10.8	-0.14	7.2	7.1	0.00
40-44	9.0	9.7	-0.02	9.2	9.3	0.00
45-49	11.1	9.4	0.06	11.2	11.6	-0.01
50-54	13.6	9.7	0.12	13.4	13.8	-0.01
55-59	13.3 12.0	8.5 5.6	0.16 0.23	13.3 11.6	13.7 12.1	-0.01 -0.01
60-64 65-69	5.5	1.8	0.23	5.2	5.2	0.00
70-74	4.2	1.2	0.18	4.0	4.0	0.00
75-79	3.4	1.0	0.16	3.3	3.3	0.00
80-84	2.9	0.8	0.16	2.8	2.8	0.00
85-89	2.2	0.7	0.13	2.1	2.2	-0.01
90-94	0.1	0.1	0.02	0.1	0.1	0.01
Gender: female Race	69.6	71.9	-0.05	69.9	70.0	0.00
race = Black or African American	17.7	27.5	-0.24	17.9	17.0	0.02
race = Other Race	20.1	17.8	0.06	20.8	21.5	-0.02
race = White	62.2	54.7	0.15	61.3	61.4	0.00
Ethnicity	1.0	0.0	0.04	4 7	4 7	0.00
ethnicity = Hispanic or Latino	1.6	2.2	-0.04	1.7	1.7	0.00
ethnicity = Not Hispanic or Latino	18.4	15.7	0.07	19.1	19.8	-0.02
Medical history: General	31.0	34.5	-0.08	30.3	29.8	0.01
Acute respiratory disease Attention deficit hyperactivity disorder	2.1	3.8	-0.10	2.1	2.0	0.01
Chronic liver disease	4.4	3.2	0.06	4.1	4.3	-0.01
Chronic obstructive lung disease	16.5	9.3	0.22	15.3	15.5	-0.01
Crohn's disease	0.6	0.4	0.03	0.5	0.5	0.00
Dementia	2.0	0.8	0.10	1.7	1.7	0.00
Depressive disorder	30.0	26.3	0.08	28.8	29.2	-0.01
Diabetes mellitus	22.6	15.1	0.19	21.7	22.3	-0.01
Gastroesophageal reflux disease	21.8	16.4	0.14	20.4	20.9	-0.01
Gastrointestinal hemorrhage	3.9	2.8	0.06	2.1	2.1	-0.01
Human immunodeficiency virus infection	0.6	0.7	-0.01	0.6	0.6	0.00
Hyperlipidemia	31.4	21.9	0.22	30.6	31.8	-0.03
Hypertensive disorder	45.7	33.3	0.26	44.0	44.7	-0.01
Lesion of liver	1.3	0.8	0.04	1.0	1.1	0.00
Obesity	14.9	14.9	0.00	14.4	14.6	-0.01
Osteoarthritis	38.7	22.6	0.36	36.6	37.8	-0.03
Pneumonia	5.4	3.4	0.10	4.8	4.8	0.00
Psoriasis	1.0	0.7	0.03	1.0	1.0	0.00
Renal impairment	4.5	3.0	0.08	3.9	4.1	-0.01
Rheumatoid arthritis	4.1 3.0	2.0 2.1	0.13 0.06	3.8 2.6	4.1 2.6	-0.02 0.00
Schizophrenia Ulcerative colitis	0.4	0.2	0.00	0.3	0.3	-0.01
Urinary tract infectious disease	13.2	14.5	-0.04	12.4	12.6	0.00
Viral hepatitis C	3.2	2.4	0.05	3.0	3.2	-0.01
Visual system disorder	31.6	27.6	0.09	30.7	31.0	-0.01
Medical history: Cardiovascular disease	•				•	
Atrial fibrillation	2.5	1.1	0.11	2.2	2.4	-0.02
Cerebrovascular disease	5.1	3.1	0.10	4.6	4.7	0.00
Coronary arteriosclerosis	8.9	4.5	0.18	8.1	8.5	-0.02
Heart disease	23.7	14.2	0.25	21.7	22.3	-0.01
Heart failure	6.2	3.3	0.14	5.5	5.6	-0.01
Ischemic heart disease	6.3	3.4	0.13	5.7	5.9	-0.01
Peripheral vascular disease	11.9	6.4	0.19	10.8	11.3	-0.02
Pulmonary embolism	1.1	0.5	0.07	0.9	0.9	-0.01
Venous thrombosis	3.0	1.6	0.09	2.6	2.6	0.00
Medical history: Neoplasms	4.0	۰	0.07	4.0		0.00
Hematologic neoplasm	1.2	0.5	0.07	1.0	1.0	0.00
Malignant lymphoma	0.4	0.2	0.03	0.3	0.3	0.00
Malignant neoplasm of anorectum Malignant neoplastic disease	0.2 6.3	0.1 3.2	0.04 0.15	0.2 5.6	0.2 5.7	0.00
Malignant tumor of breast	1.5	0.8	0.15	1.4	1.6	-0.01
Malignant tumor of colon	0.4	0.8	0.04	0.3	0.3	0.00
Malignant tumor of lung	0.5	0.1	0.04	0.4	0.4	0.00
Malignant tumor of urinary bladder	0.2	0.1	0.03	0.2	0.1	0.00
Primary malignant neoplasm of prostate	0.4	0.2	0.04	0.3	0.3	0.00
Medication use		•	· · -		-	
Agents acting on the renin-angiotensin system	49.5	32.4	0.35	48.4	49.7	-0.03
Antibacterials for systemic use	72.3	72.9	-0.01	71.5	72.1	-0.01
Antidepressants	61.2	51.0	0.21	59.8	61.0	-0.02

```
Antiepileptics
                                                                                                                                               -0.02
                                                                                                    0.04
                                                                                     0.0
14.7
6.7
9.7
Antiinflammatory and antirheumatic products
                                                                                                    0.01
                                                                                                                0.0
                                                                                                                                 0.0
                                                                                                                                                0.00
                                                                                                    0.08
Antineoplastic agents
                                                                                                               16.3
Antipsoriatics
                                                                                                    0.04
                                                                                                                                  8.1
                                                                                                                                               -0.02
                                                                                                    0.31
                                                                                                                                  19.0
                                                                                                                                               -0.02
Antithrombotic agents
Beta blocking agents
Calcium channel blockers
                                                                                     36.6
                                                                                                    0.29
                                                                                                               49.6
                                                                                                                                  50.5
                                                                                                                                               -0.02
Diuretics
                                                                  59.8
                                                                                     44.4
                                                                                                    0.31
                                                                                                               58.6
                                                                                                                                 59.6
                                                                                                                                               -0.02
Drugs for acid related disorders
Drugs for obstructive airway diseases
                                                                                                                                  56.4
                                                                                     55.1
                                                                                                    0.03
                                                                                                                                               -0.01
Drugs used in diabetes
                                                                                     19.0
                                                                                                    0.25
                                                                                                                                  29.9
Immunosuppressants
                                                                   3.4
                                                                                      1.7
                                                                                                    0.11
                                                                                                                3.2
                                                                                                                                  3.5
                                                                                                                                               -0.02
                                                                                                                                 42.8
73.2
82.2
Lipid modifying agents
                                                                                     73.5
78.2
                                                                                                    0.00
                                                                                                               72.6
                                                                                                                                               -0.01
Opioids
Psycholeptics
                                                                                                    0.10
                                                                                                               81.5
                                                                                                                                               -0.02
Psychostimulants, agents used for adhd and nootropics
                                                                                                   -0.02
```

5.6 Inserting the population cohort in the database

For various reasons it might be necessary to insert the study population back into the database, for example because we want to use an external cohort characterization tool. We can use the insertDbPopulation function for this purpose:

This function will store the population in a table with the same structure as the cohort table in the CDM, in this case in the same table where we had created our original cohorts.

6 Follow-up and power

Before we start fitting an outcome model, we might be interested to know whether we have sufficient power to detect a particular effect size. It makes sense to perform these power calculations once the study population has been fully defined, so taking into account loss to the various inclusion and exclusion criteria (such as no prior outcomes), and loss due to matching and/or trimming. Since the sample size is fixed in retrospective studies (the data has already been collected), and the true effect size is unknown, the CohortMethod package provides a function to compute the minimum detectable relative risk (MDRR) instead:

```
#> targetPersons comparatorPersons targetExposures comparatorExposures targetDays comparatorDays totalOutcomes mdrr se
#> 1 47377 339648 47377 339648 6609395 23763641 1215 1.277903 0.08752912
```

In this example we used the studyPop object, so the population before any matching or trimming. If we want to know the MDRR after matching, we use the matchedPop object we created earlier instead:

```
computeMdrr(population = matchedPop,
    modelType = "cox",
    alpha = 0.05,
    power = 0.8,
    twoSided = TRUE)
```

```
#> targetPersons comparatorPersons targetExposures comparatorExposures targetDays comparatorDays totalOutcomes mdrr se
#> 1 44960 44960 44960 44960 6198447 3939759 425 1.312316 0.09701425
```

Even thought the MDRR in the matched population is higher, meaning we have less power, we should of course not be fooled: matching most likely eliminates confounding, and is therefore preferred to not matching.


To gain a better understanding of the amount of follow-up available we can also inspect the distribution of follow-up time. We defined follow-up time as time at risk, so not censored by the occurrence of the outcome. The getFollowUpDistribution can provide a simple overview:

getFollowUpDistribution(population = matchedPop)

```
#> 100% 75% 50% 25% 0% Treatment
#> 1 2 61 61 137 3764 1
#> 2 2 46 61 83 3026 0
```

The output is telling us number of days of follow-up each quantile of the study population has. We can also plot the distribution:

plotFollowUpDistribution(population = matchedPop)



7 Outcome models

The outcome model is a model describing which variables are associated with the outcome.

7.1 Fitting a simple outcome model

In theory we could fit an outcome model without using the propensity scores. In this example we are fitting an outcome model using a Cox regression:

```
outcomeModel <- fitOutcomeModel(population = studyPop,</pre>
                                  modelType = "cox")
outcomeModel
#> Model type: cox
#> Stratified: FALSE
#> Use covariates: FALSE
#> Use inverse probability of treatment weighting:
#> Status: OK
#>
#>
             Estimate lower .95 upper .95
                                                logRr seLogRr
#> treatment 1.038993 0.899015 1.196863 0.038252
But of course we want to make use of the matching done on the propensity score:
outcomeModel <- fitOutcomeModel(population = matchedPop,</pre>
                                  modelType = "cox",
                                  stratified = TRUE)
outcomeModel
#> Model type: cox
#> Stratified: TRUE
#> Use covariates: FALSE
#> Use inverse probability of treatment weighting:
#> Status: OK
#>
#>
             Estimate lower .95 upper .95
                                                logRr seLogRr
#> treatment 0.80292
                         0.62382
                                    1.03105 -0.21950 0.1282
Note that we define the sub-population to be only those in the matchedPop object, which we created earlier
```

Note that we define the sub-population to be only those in the matchedPop object, which we created earlier by matching on the propensity score. We also now use a stratified Cox model, conditioning on the propensity score match sets.

Instead of matching or stratifying we can also perform Inverse Probability of Treatment Weighting (IPTW):

logRr seLogRr

7.2 Adding interaction terms

#> treatment 0.84688

Estimate lower .95 upper .95

#> #>

We may be interested whether the effect is different across different groups in the population. To explore this, we may include interaction terms in the model. In this example we include three interaction terms:

0.78180 0.91747 -0.16619 0.0408

```
stratified = TRUE, interactionCovariateIds = interactionCovariateIds)


outcomeModel

#> Model type: cox
#> Stratified: TRUE
#> Use covariates: FALSE
#> Use provariates: FALSE
```

Note that you can use the grepCovariateNames to find covariate IDs.

It is prudent to verify that covariate balance has also been achieved in the subgroups of interest. For example, we can check the covariate balance in the subpopulation of females:

#> Warning: Removed 10364 rows containing missing values (geom_point).



7.3 Adding covariates to the outcome model

One final refinement would be to use the same covariates we used to fit the propensity model to also fit the outcome model. This way we are more robust against misspecification of the model, and more likely to remove bias. For this we use the regularized Cox regression in the Cyclops package. (Note that the treatment variable is automatically excluded from regularization.)

```
modelType = "cox",
                                stratified = TRUE,
                                useCovariates = TRUE)
outcomeModel
#> Model type: cox
#> Stratified: TRUE
#> Use covariates: TRUE
#> Use inverse probability of treatment weighting:
#> Status: OK
#> Prior variance: 0.0417214627426502
#>
#>
             Estimate lower .95 upper .95
                                             logRr seLogRr
                      0.63285 1.14949 -0.16029 0.1523
#> treatment 0.85190
     Inpecting the outcome model
We can inspect more details of the outcome model:
summary(outcomeModel)
#> Model type: cox
#> Stratified: TRUE
#> Use covariates: TRUE
#> Use inverse probability of treatment weighting:
```

```
#> Status: OK
#> Prior variance: 0.0417214627426502
#>
#>
             Estimate lower .95 upper .95
                                              logRr seLogRr
#> treatment 0.85190 0.63285 1.14949 -0.16029 0.1523
#>
#> Population counts
#>
         treatedPersons comparatorPersons treatedExposures comparatorExposures
#> Count
                 44840
                                    44840
                                                      44840
#>
#> Outcome counts
        treatedPersons comparatorPersons treatedExposures comparatorExposures treatedOutcomes
#>
#> Count
                    245
                                      196
                                                        245
#>
#> Time at risk
       treatedDays comparatorDays
#> Days
            6144026
                           3904722
exp(coef(outcomeModel))
#> [1] 0.8518951
exp(confint(outcomeModel))
#> [1] 0.6328451 1.1494942
We can also see the covariates that ended up in the outcome model:
fullOutcomeModel <- getOutcomeModel(outcomeModel, cohortMethodData)</pre>
head(fullOutcomeModel)
```


#> coefficient id covariateName

```
#> 2
        0.5499190
                    198124210 ... 0 days relative to index: Kidney disease
#> 1
        0.4828838
                      8507001
                                                             gender = MALE
#> 8
        0.3252432
                   2514408502 ...nation; Medical decision making of moder
#> 26
        0.3017819 21601664412 ... relative to index: BETA BLOCKING AGENTS
#> 17
        0.2805469
                   4329041212 ...0 through 0 days relative to index: Pain
#> 4
        0.2762147
                    321588210 ... O days relative to index: Heart disease
```

7.5 Kaplan-Meier plot

We can create the Kaplan-Meier plot:

```
plotKaplanMeier(matchedPop, includeZero = FALSE)
```




Note that the Kaplan-Meier plot will automatically adjust for any stratification, matching, or trimming that may have been applied.

7.6 Time-to-event plot

We can also plot time-to-event, showing both events before and after the index date, and events during and outside the defined time-at-risk window. This plot can provide insight into the temporal pattern of the outcome relative to the exposures:

```
plotTimeToEvent(cohortMethodData = cohortMethodData, outcomeId = 3, firstExposureOnly = FALSE, washoutP
    riskWindowEnd = 30, addExposureDaysToEnd = TRUE)
```



Note that this plot does not show any adjustment for the propensity score.

8 Acknowledgments

 $year = \{2019\},\$

citation("CohortMethod")

#> #>

#>

Considerable work has been dedicated to provide the ${\tt CohortMethod}$ package.

```
#>
#>
To cite package 'CohortMethod' in publications use:
#>
#> Martijn Schuemie, Marc Suchard and Patrick Ryan (2019). CohortMethod: New-user cohort method with
#> https://ohdsi.github.io/CohortMethod, https://github.com/OHDSI/CohortMethod.
#>
#> A BibTeX entry for LaTeX users is
#>
#> @Manual{,
#> title = {CohortMethod: New-user cohort method with large scale propensity and outcome models},
```

note = {https://ohdsi.github.io/CohortMethod, https://github.com/OHDSI/CohortMethod},

Further, CohortMethod makes extensive use of the Cyclops package.

author = {Martijn Schuemie and Marc Suchard and Patrick Ryan},

citation("Cyclops")

```
#> To cite Cyclops in publications use:
#>
#> Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D (2013). "Massive parallelization of serial infer
#> Modeling and Computer Simulation_, *23*, 10. <URL: http://dl.acm.org/citation.cfm?id=2414791>.
#> A BibTeX entry for LaTeX users is
#>
#>
    @Article{,
#>
       author = {M. A. Suchard and S. E. Simpson and I. Zorych and P. Ryan and D. Madigan},
#>
       title = {Massive parallelization of serial inference algorithms for complex generalized linear m
       journal = {ACM Transactions on Modeling and Computer Simulation},
#>
#>
       volume = \{23\},
#>
       pages = \{10\},
#>
       year = {2013},
#>
       url = {http://dl.acm.org/citation.cfm?id=2414791},
#>
```

This work is supported in part through the National Science Foundation grant IIS 1251151.